CEO Professor Alan Trounson AO said, “The successful capital raising, in times of scant investment support in biotechnology, is welcome and further supports confidence in the company for the delivery of effective therapies in ovarian cancer and other difficult diseases.” …
Latest Video
New Stories
-
Medicines Australia strikes cautious tone on HTA review implementation group
October 2, 2024 - - Latest News -
AbbVie heads the list of Australia's best workplaces in pharma and biotech
October 2, 2024 - - Latest News -
Sigma offers court-enforceable undertaking in response to ACCC concerns
October 2, 2024 - - Latest News -
Pfizer renews commitment to all patients during fourth annual patient week
October 2, 2024 - - Latest News -
Australian company Vaxxas receives significant investment from Endpoints Capital
October 1, 2024 - - Australian Biotech -
Cartherics raises over $15 million in private financing round
October 1, 2024 - - Australian Biotech -
Nyrada’s says lead drug candidate demonstrates significant cardioprotection
October 1, 2024 - - Latest News